JPRN-UMIN000010614已完成未知
Efficacy of once daily human GLP-1 analogue, Liraglutide on dietary lifestyle and treatment satisfaction in type 2 diabetic patients. - Efficacy of Liraglutide on dietary lifestyle and treatment satisfaction
Osaka Saiseikai Noe Hospital0 个研究点目标入组 100 人开始时间: 2013年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Contraindication of Liraglutide Comorbidity of endocrine disease except diabetes. Existence of severe diabetic complication like diabetic nephropathy severer than grade III by criteria of Japan Diabetes Society and diabetic retinopathy severer than by criteria of Japan Diabetes Society.
研究者
相似试验
已完成
不适用
Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetesJPRN-UMIN000009638Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine130
进行中（未招募）
不适用
ELAD StudyEUCTR2013-000962-13-GBImperial College London
进行中（未招募）
1 期
A pilot study in the use of the GLP-1 agonist liraglutide in the treatment of short bowelIntestinal failure with an underlying aetiology of short bowelMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-004797-18-GBImperial College London5
进行中（未招募）
1 期
EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAPeripheral Artery Disease and type 2 diabetes mellitusMedDRA version: 20.0Level: LLTClassification code 10053246Term: Type II diabetes peripheral angiopathySystem Organ Class: 100000004866EUCTR2020-002940-22-ITA.O.U. Università degli Studi della Campania Luigi Vanvitelli50
进行中（未招募）
不适用
Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targets with premixed insulin strategy10 patients (both gender) under treatment with premixed insulin (2-3 injections) and HbA1c>7% will be switched to basal insulin glargine (Lantus, once daily) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily).EUCTR2013-005334-37-ATMedical University of Vienna / Medizinische Universität Wien